CASI Pharmaceuticals (CASIF) Receivables - Net (2021 - 2025)

CASI Pharmaceuticals (CASIF) has 5 years of Receivables - Net data on file, last reported at $4.1 million in Q4 2025.

• Quarterly Receivables - Net fell 73.33% year-over-year to $4.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.1 million (down 73.33% YoY) and the FY2025 annual result came in at $4.1 million, down 73.33% from the prior year.
• Receivables - Net climbed to $4.1 million in Q4 2025, from $2.6 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $12.5 billion in Q2 2023 to a low of $2.6 million in Q3 2025.
• A 5-year average of $3.3 billion and a median of $13.0 million in 2022 frame the typical range for Receivables - Net.
• The widest YoY moves for Receivables - Net: up 129659.26% in 2025, down 99.92% in 2025.
• Tracing CASIF's Receivables - Net over 5 years: stood at $9.8 million in 2021, then soared by 32.34% to $13.0 million in 2022, then soared by 73522.14% to $9.6 billion in 2023, then slumped by 99.84% to $15.3 million in 2024, then plunged by 73.33% to $4.1 million in 2025.
• The last three Receivables - Net figures came in at $4.1 million (Q4 2025), $2.6 million (Q3 2025), and $5.4 million (Q2 2025), per Business Quant data.